Skip to content

PP&E (Net) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$7.66B+6.2%
Eli Lilly logo
Eli LillyLLY
$26.54B+43.7%
Pfizer logo
PfizerPFE
$19.4B+5.8%
Amgen logo
AmgenAMGN
$8.22B+23.0%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$31.48M+15.9%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$6.38M-15.4%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s PP&E (net)?
Erasca, Inc. (ERAS) reported PP&E (net) of $12.61M in Q1 2026.
How has Erasca, Inc.'s PP&E (net) changed year-over-year?
Erasca, Inc.'s PP&E (net) decreased by 19.1% year-over-year, from $15.59M to $12.61M.
What is the long-term trend for Erasca, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), Erasca, Inc.'s PP&E (net) has grown at a 48.4% compound annual growth rate (CAGR), from $1.85M to $13.3M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.